Grech, Olivia http://orcid.org/0000-0001-5560-802X
Mitchell, James L.
Lyons, Hannah S.
Yiangou, Andreas http://orcid.org/0000-0001-8905-5734
Thaller, Mark
Tsermoulas, Georgios
Brock, Kristian
Mollan, Susan P. http://orcid.org/0000-0002-6314-4437
Sinclair, Alexandra J. http://orcid.org/0000-0003-2777-5132
Funding for this research was provided by:
Brain Research UK PhD Studentship
Ministry of Defence
Association of British Neurologists and Guarantors of the Brain fellowship.
DH | National Institute for Health Research (NIHR-CS-011-028)
RCUK | Medical Research Council (MR/K015184/1)
Sir Jules Thorn Charitable Trust (Award for Biomedical Science)
Article History
Received: 11 August 2023
Revised: 14 December 2023
Accepted: 14 December 2023
First Online: 11 January 2024
Competing interests
: OG reports scientific consultancy fees from Invex therapeutics (2020). AY reports receiving speaker fees from Teva, UK, outside the submitted work. KB works for UCB. SM reports consultancy fees (Invex Therapeutics; Neurodiem); advisory board fees (Invex therapeutics; Janssen; Gensight; Abbie Vie) and speaker fees (Heidelberg engineering; Chugai-Roche Ltd; Allergan; Santen; Chiesi; and Santhera). AJS reports personal fees from Invex therapeutics in her role as Director with stock holdings, during the conduct of the study (since 28.06.2019); other for advisory boards from Allergan, Novartis, Cheisi and Amgen outside the submitted work. All other authors declare no competing interests.